Monte Rosa Therapeutics, Inc.
GLUE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GLUE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLUE
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company developing molecular glue degrader (MGD) therapies, with a lead candidate MRT-6160 in Phase 2 and a cash runway into 2029.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.14B
Cash Runway
17.4 moLead Asset
mrt-2359 (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials · 1 catalyst for Monte Rosa Therapeutics, Inc..
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company developing molecular glue degrader (MGD) therapies, with a lead candidate MRT-6160 in Phase 2 and a cash runway into 2029.
- Monte Rosa is focused on developing molecular glue degraders (MGDs), a novel therapeutic modality [sec].
- Lead candidate MRT-6160 is in Phase 2 clinical development, with a topline readout expected by 2026-12-31 [catalyst].
- As of 2026-06-30, the company reported cash & equivalents of $95.0M and total revenue of $9.0M [sec].
- Net loss for the six months ended June 30, 2026 was $43.4M, with an accumulated deficit of $565.1M as of June 30, 2026 [sec_mda].
- Management expects existing cash and marketable securities to fund operations into 2029 [sec_mda].
What works
- Cash runway is projected into 2029, providing a multi-year operational buffer without near-term financing pressure [sec_mda · as of 2026-08-06].
- The company has a promising Phase 2 catalyst for MRT-6160 by end of 2026, which could de-risk the pipeline [catalyst].
- Monte Rosa is pursuing a differentiated mechanism (molecular glue degraders) that may offer advantages over traditional small molecules [sec].
What to weigh
- The company has a significant accumulated deficit of $565.1M as of June 30, 2026, reflecting years of R&D spending without approved products [sec_mda · as of 2026-08-06].
- Net loss of $43.4M for the six months ended June 30, 2026 indicates ongoing cash burn [sec].
- The company is entirely pre-revenue from product sales and will need to delay, reduce, or terminate activities if additional capital is not raised [sec_mda · as of 2026-08-06].
- Clinical development risks are high, as the company notes numerous uncertainties in research, development, and regulatory approval [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash runway into 2029
“We anticipate that our existing cash and cash equivalents and marketable securities support our cash runway into 2029.”
SEC MD&A · August 6, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $565.1 million”
SEC MD&A · August 6, 2026
Net loss for six months ended June 30, 2026
“loss of $38.6 million.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · mrt-6160 — Phase 2 Readout: mrt-6160 — Topline results from the Phase 2 study of MRT-6160 will be a key value inflection point for the pipeline.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — MRT-6160 Phase 2 readout is a binary event; failure could significantly impair pipeline value [catalyst].
- Cash burn and funding need — Net loss of $43.4M in H1 2026 and accumulated deficit of $565.1M highlight reliance on external capital [sec_mda].
- Regulatory and development delays — Uncertainties in clinical trial timelines and regulatory approvals could delay or halt programs [sec_mda].
- No approved products — Company has no commercial products and may never generate product revenue [sec_mda].
What to watch
- Phase 2 topline data for MRT-6160 expected by 2026-12-31 [catalyst].
- Cash burn rate and any updates to cash runway guidance [sec_mda].
- Progress of MRT-2359 combination study in heavily pretreated patients [sec].
- Any partnership, licensing, or financing announcements that could extend runway or validate platform [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Monte Rosa Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Monte Rosa Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
17.4 months
D/E 0.42 · 0% dilution
Lead: Phase 2
1 candidate
1 upcoming, next in ~123d
0 buys · 23 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$1.12B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,200,490 | $102.0M |
| blackrock, inc. | 5,637,684 | $92.7M |
| bvf inc/il | 4,460,886 | $73.4M |
| baker bros. advisors lp | 4,345,736 | $71.5M |
| suvretta capital management, llc | 4,226,809 | $69.5M |
| state street corp | 3,353,980 | $55.2M |
| braidwell lp | 3,206,574 | $52.7M |
| versant venture management, llc | 3,180,780 | $52.3M |
| american century companies inc | 2,809,647 | $46.2M |
| silverarc capital management, llc | 2,002,040 | $32.9M |
Showing top 10 of 187 institutional holders of Monte Rosa Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 20.6%
- Days to cover
- 10.8
- Shares short
- 13,398,925
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GLUE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company developing molecular glue degrader (MGD) therapies, with a lead candidate MRT-6160 in Phase 2 and a cash runway into 2029.
What is Monte Rosa Therapeutics, Inc.'s lead drug candidate?
Monte Rosa Therapeutics, Inc.'s most advanced tracked candidate is mrt-2359 (Phase 2) for NSCLC; Castration-Resistant Prostate Cancer (CRPC).
What is Monte Rosa Therapeutics, Inc.'s next catalyst?
Monte Rosa Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: mrt-6160" — expected December 31, 2026.
Who is the CEO of Monte Rosa Therapeutics, Inc.?
Dr. Markus Warmuth M.D. is the chief executive officer of Monte Rosa Therapeutics, Inc. (GLUE).
Where is Monte Rosa Therapeutics, Inc. headquartered?
Monte Rosa Therapeutics, Inc. (GLUE) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.